TCR2 Therapeutics to Present at the 2018 Keystone Symposia Conference on Emerging Cellular Therapies: T Cells and Beyond

CAMBRIDGE, Mass., Feb. 5, 2018 /PRNewswire/ -- TCR² Therapeutics Inc. announced today that its Chief Scientific Officer, Robert Hofmeister, Ph.D., has been invited to present at the prestigious Keystone Symposia Conference on Emerging Cellular Therapies: T Cells and Beyond being held February 11-15 in Keystone, Colorado. Dr. Hofmeister has also been invited to speak at the Molecular Med Tri-Con Conference, Adoptive Cell-Based Cancer Immunotherapy Symposium, being held February 11-16 in San Francisco, California.

Dr. Hofmeister's oral presentations will discuss rationales and mechanisms for the company's HLA-independent TRuC™-T cells and provide additional updates for TC-210, the company's lead program targeting mesothelin-positive solid tumors. TC-210 is advancing into the clinic later this year for solid tumor indications including ovarian, mesothelioma, cholangiocarcinoma, pancreatic and lung cancers.

Presentation at Keystone Symposia Conference

• Title: A Novel T Cell Therapy Engaging the Complete T Cell Receptor
• Session Title: Workshop I: Perspectives from the Industry
• Date & Time: Monday, February 12, 2018 from 2:30-4:30pm MST
• Location: Keystone Resort, Keystone, CO

Presentation at Molecular Med Tri-Con Conference

• Title: TRuC™-T Cells: A Novel Kind of Engineered T Cells for Solid Tumors Exploiting the Signaling Power of the Complete T Cell Receptor
• Session Title: Next-Generation CAR-T Discovery and Development
• Date & Time: Friday, February 16, 2018 at 11:15am PST
• Location: Hilton San Francisco, San Francisco, CA

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

SOURCE TCR2 Therapeutics

Related Links

http://www.tcr2.com